MSCI Expands Partnership with Google Cloud to Accelerate Generative AI Solutions for the Investment Industry
29.8.2023 15:00:00 EEST | Business Wire | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, today announced an expansion of its partnership with Google Cloud to accelerate the development of generative AI (gen AI) solutions for the investment industry. Powered by Google Cloud’s gen AI platform Vertex AI and climate technology, including BigQuery Geospatial and Earth Engine, the solutions will help MSCI clients better manage portfolio risks and opportunities and make informed investment decisions.
The partnership will focus on three key areas:
- Risk Signals: MSCI will combine its proprietary data and analytics with Google Cloud’s gen AI solutions to provide an overview of portfolio and enterprise level risk designed to significantly reduce the time clients need to analyze and arrive at actionable insights. This solution will help portfolio and risk managers more easily synthesize and rapidly act on significant volumes of risk signals from their portfolios, while also fostering greater collaboration between risk and portfolio management teams to build more resilient portfolios.
- Conversational AI: Google Cloud’s gen AI will also power MSCI’s new conversational AI solution for its portfolio and risk management solutions. This capability will use natural language processing to simulate human language and generate responses that can enable clients to quickly answer questions and surface information about their portfolios and MSCI data, models, and solutions.
- Climate Generative AI: MSCI and Google Cloud will work together to leverage Google’s gen AI technologies to help investors measure and manage portfolio exposure to climate risk and identify low carbon investment opportunities. With these advanced AI technologies, MSCI will make it easier for investors to identify, synthesize, and communicate the broad range of climate exposures across asset classes.
“The AI revolution has led to rising expectations among companies and investors, who want faster access to higher-quality data, analytics, and actionable insights,” said Henry Fernandez, Chairman and Chief Executive Officer, MSCI. “Expanding our partnership with Google Cloud will help MSCI address these needs while keeping us at the forefront of advanced data technologies. It will also help us provide new solutions for investors working to decarbonize their portfolios.”
“The investment industry has long been fueled by AI and machine learning, which MSCI has been using for years. However, advancement in generative AI has jump-started a revolution in our industry,” added Jigar Thakkar, Chief Technology Officer, MSCI. “We are excited to collaborate with Google Cloud to accelerate the development of generative AI solutions, which will aim to offer investors deeper data-driven insights, enhanced decision-making capabilities, and accelerated portfolio implementation. With the power of generative AI and LLMs, we are advancing towards our commitment to help investors build better portfolios with enhanced insights.”
“Generative AI is driving the next evolution of financial services as investment professionals look for better and faster ways to monitor portfolios, generate new insights, and scale the speed of decision-making,” said Thomas Kurian, CEO, Google Cloud. “Our partnership with MSCI to build generative AI-powered solutions will not only help risk and portfolio management teams better collaborate and unlock insights, but also will enable MSCI’s clients to build more climate-resilient portfolios.”
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are in MSCI’s Annual Report on Form 10-K for the most recent fiscal year ended on December 31 that is filed with the SEC. MSCI does not undertake to update any forward-looking statements. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230829773754/en/
Contact information
Media Inquiries
PR@msci.com
Samuel Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049
Konstantinos Makrygiannis +44 (0) 7768 930056
Tina Tan +852 2844 9320
MSCI Global Client Services
EMEA Client Service +44 20 7618.2222
Americas Client Service +1 888 588 4567 (toll free)
Asia Pacific Client Service +852 2844 9333
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom